Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism  Gerald A. Colvin, David Berz, Muthalagu.

Slides:



Advertisements
Similar presentations
Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
Advertisements

Cytokine and Chemokine Patterns Across 100 Days after Hematopoietic Stem Cell Transplantation in Children  Joseph DiCarlo, Rajni Agarwal-Hashmi, Ami Shah,
Haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for treatment of hematological malignancies in children  Daihong.
Evaluation of Minimal Residual Disease by Real-Time Quantitative PCR of Wilms’ Tumor 1 Expression in Patients with Acute Myelogenous Leukemia after Allogeneic.
Bone Marrow Graft-versus-Host Disease: Evaluation of Its Clinical Impact on Disrupted Hematopoiesis after Allogeneic Hematopoietic Stem Cell Transplantation 
William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved  Nicolas Novitzky,
CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults 
Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J
A Prospective Study of Iron Overload Management in Allogeneic Hematopoietic Cell Transplantation Survivors  Navneet S. Majhail, Hillard M. Lazarus, Linda.
Targeting CD138−/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity  Lawrence G. Lum, Archana.
Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute.
Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer by Jeffrey S. Miller, Yvette Soignier, Angela.
Chimerism-Based Pre-Emptive Immunotherapy with Fast Withdrawal of Immunosuppression and Donor Lymphocyte Infusions after Allogeneic Stem Cell Transplantation.
Gastrointestinal Acute Graft-versus-Host Disease in Children: Histology for Diagnosis, Mesenchymal Stromal Cells for Treatment, and Biomarkers for Prediction.
A Role for TNF Receptor Type II in Leukocyte Infiltration into the Lung during Experimental Idiopathic Pneumonia Syndrome  Gerhard C. Hildebrandt, Krystyna.
Effects of the NK Cell Recovery on Outcomes of Unmanipulated Haploidentical Blood and Marrow Transplantation for Patients with Hematologic Malignancies 
Donor-Derived Natural Killer Cells Infused after Human Leukocyte Antigen– Haploidentical Hematopoietic Cell Transplantation: A Dose-Escalation Study  Inpyo.
High Rabbit-Antihuman Thymocyte Globulin Levels Are Associated with Low Likelihood of Graft-vs-Host Disease and High Likelihood of Posttransplant Lymphoproliferative.
PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model)  Yehudith Azar, Reut.
Combined CD4+ Donor Lymphocyte Infusion and Low-Dose Recombinant IL-2 Expand FOXP3+ Regulatory T Cells following Allogeneic Hematopoietic Stem Cell Transplantation 
Adoptive Cellular Therapy using Cells Enriched for NKG2D+CD3+CD8+T Cells after Autologous Transplantation for Myeloma  Kenneth R. Meehan, Laleh Talebian,
FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides.
A Phase II Multicenter Study of Visilizumab, Humanized Anti-CD3 Antibody, to Treat Steroid-Refractory Acute Graft-versus-Host Disease  Paul A. Carpenter,
The Effects of Interleukin 10 and Interferon γ Cytokine Gene Polymorphisms on Survival after Autologous Bone Marrow Transplantation for Patients with.
Sabina Kersting, Leo F. Verdonck 
Cytomegalovirus Immune Reconstitution Occurs in Recipients of Allogeneic Hematopoietic Cell Transplants Irrespective of Detectable Cytomegalovirus Infection 
Suppression of natural killer cells in the presence of CD34+ blood progenitor cells and peripheral blood lymphocytes  J. Clausen, M. Enk, B. Vergeiner,
Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation  David Nachbaur, Petra Schumacher,
Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility?  Jason W. Chien, Keith M. Sullivan  Biology.
The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review  Denise M.
Posttransplant Thrombopoiesis Predicts Survival in Patients Undergoing Autologous Hematopoietic Progenitor Cell Transplantation  Mary J. Ninan, Christopher.
Efficacy and Safety of Ex Vivo Cultured Adult Human Mesenchymal Stem Cells (Prochymal™) in Pediatric Patients with Severe Refractory Acute Graft-Versus-Host.
Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Controversies in Lymphoma: The Role of Hematopoietic Cell Transplantation for Mantle Cell Lymphoma and Peripheral T Cell Lymphoma  Peter Dreger, Ginna.
Lymphocyte Subset Recovery and Outcome after Autologous Hematopoietic Stem Cell Transplantation for Plasma Cell Myeloma  Jessica Rueff, Michael Medinger,
Volume 23, Issue 9, Pages (September 2015)
Donor Lymphocyte Infusion–Mediated Graft-versus-Host Responses in a Preclinical Swine Model of Haploidentical Hematopoietic Cell Transplantation  Raimon.
Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation  Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport 
Reconstitution of Interleukin-17–Producing T Helper Cells after Allogeneic Hematopoietic Cell Transplantation  Felix Bahr, Rebekka Wehner, Uwe Platzbecker,
Allogeneic Transplantation for Pediatric Acute Lymphoblastic Leukemia: The Emerging Role of Peritransplantation Minimal Residual Disease/Chimerism Monitoring.
Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease  Caron A. Jacobson, Lixian Sun, Haesook.
Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.
Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients  Pooja Khandelwal, Sabine Mellor-Heineke, Najibah.
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic.
Volume 23, Issue 1, Pages (January 2015)
Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin
Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg 
Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects  Jeffrey S. Moyer, Gabriel.
Haploidentical/Mismatched Hematopoietic Stem Cell Transplantation without In Vitro T Cell Depletion for T Cell Acute Lymphoblastic Leukemia  Yu Wang,
Pauline Damien, David S. Allan 
Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation  Patrick.
What is quality in a transplant program?
Diarrhea during the Conditioning Regimen Is Correlated with the Occurrence of Severe Acute Graft-versus-Host Disease through Systemic Release of Inflammatory.
Robin L. Williams, Sarah Cooley, Veronika Bachanova, Bruce R
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
Quantitative and Qualitative CD4 T Cell Immune Responses Related to Adenovirus DNAemia in Hematopoietic Stem Cell Transplantation  Valérie Guérin-El Khourouj,
Volume 21, Issue 11, Pages (November 2013)
Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Frédéric Baron, Rainer Storb 
Treatment versus Transplant for Challenging Hematologic Disorders
Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
Mary Eapen  Biology of Blood and Marrow Transplantation 
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
Endothelial Vulnerability and Endothelial Damage Are Associated with Risk of Graft- versus-Host Disease and Response to Steroid Treatment  Sascha Dietrich,
Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H
Presentation transcript:

Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without Chimerism  Gerald A. Colvin, David Berz, Muthalagu Ramanathan, Eric S. Winer, Loren Fast, Gerald J. Elfenbein, Peter J. Quesenberry  Biology of Blood and Marrow Transplantation  Volume 15, Issue 4, Pages 421-431 (April 2009) DOI: 10.1016/j.bbmt.2008.12.503 Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Hematopoietic kinetics and toxicity: patient cell counts. (A) Median WBC count, ANC, and platelet count of patients with hematologic (n = 26) and solid tumor (n = 15) malignancies at various times after transplantation. (B) Treatment-related toxicity of all patients graded according to Eastern Cooperative Oncology Group criteria using a toxicity array. Each patient is represented from left to right, with the patient number listed on the top of the array and each toxicity grade depicted in vertical columns. Because many patients already had grade 4 toxicity resulting from their disease, the grade of toxicity deviation from baseline is presented, to show actual treatment-related toxicity. Biology of Blood and Marrow Transplantation 2009 15, 421-431DOI: (10.1016/j.bbmt.2008.12.503) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 HIS characteristics: an example of skin changes with the syndrome. (A) Day 4 after cell infusion. (B) Day +9. (C) Histological section obtained on day 4 showing spongiosis and lymphocyte invasion with no evidence of GVHD. Biology of Blood and Marrow Transplantation 2009 15, 421-431DOI: (10.1016/j.bbmt.2008.12.503) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Multiplex cytokine analysis of serum. Cytokine levels were measured using the Human 17-Plex Panel Cytokine Assay (IL-1, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 [p70], IL-13, IL-17, G-CSF, GM-CSF, IFN-γ MCP-1 [MCAF], MIP-1β, TNF-α) and the Bio-Plex Suspension Array System (Bio-Rad) according to the manufacturer's instructions. The results were compared against a standard curve derived from recombinant cytokine standards ranging from of 0.2 to 3200 pg/mL. Cytokine concentrations were calculated using Bio-Plex Manager software (Bio-Rad). The data are presented in pg/mL. Serial serum samples were obtained in 17 patients at the 2 × 108 CD3+ cell/kg level. Cytokine levels were evaluated immediately before any therapy and then after cell infusion in patients with HIS during fever spikes. Significant elevations (P < .05) in the 2 × 108 CD3+ cell/kg cohort (n = 17) between preinfusion and postinfusion values were seen in IL-6 (264 ± 61 vs 3757 ± 1308 pg/mL), IL-8 (21 ± 7 vs 77 ± 18 pg/mL), IL-10 (5 ± 1.7 vs 91±18.6 pg/mL), IFN-γ (3.7 ± 3.0 vs 30.9 ± 6.4 pg/mL), IL-5 (1.28 ± 0.49 vs 11.0 ± 2.7 pg/mL), IL-7 (3.7 ± 1.4 vs 7.7 ± 1.1 pg/mL), IL-13 (0.51 ± 0.28 vs 4.2 ± 1.0 pg/mL), MCP-1 (87.1 ± 25.4 vs 1188.7 ± 773 pg/mL), and MIP-1β (94.9 ± 18.5 vs 999.8 ± 773.8 pg/ml). No significant elevation or depression of IL-2, IL-4, GM-CSF, INF-α, IL-1β, IL-7, IL-12, IL-17, or G-CSF occurred. Biology of Blood and Marrow Transplantation 2009 15, 421-431DOI: (10.1016/j.bbmt.2008.12.503) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Antitumor effects and distribution kinetics of infused cells. (A) Serial CT scans of gallium avid tumor in a patient with diffuse large B cell lymphoma who remained in complete remission 60 months after haploidentical immunotherapy in the absence of any additional therapy. Note the slow tumor regression over time. The most recent restaging with PET/CT scan performed in May 2007 was negative for recurrent disease (data not shown). (B) Transient response to haplo immunotherapy as demonstrated by representative serial bone marrow results in a patient with AML. At 3 days after cell infusion, a marked response to therapy is evident, with loss of myeloblasts and some edema. At 14 days after therapy, resumption of normal hematopoiesis is seen, but by 26 days after therapy, the leukemia has returned, and the marrow is packed with myeloblasts. Biology of Blood and Marrow Transplantation 2009 15, 421-431DOI: (10.1016/j.bbmt.2008.12.503) Copyright © 2009 American Society for Blood and Marrow Transplantation Terms and Conditions